However, the isoxazole derivative NVP-AUY922 is able to deplete HER2 in breast cancer cells  and EGFR in non–small lung cancer cells  and is also under clinical evaluation for the treatment of various solid tumors (see http://www.clinicaltrials.gov/ct2/results?term=AUY922&Search=Search). Other Hsp90 small molecule inhibitors under current clinical Natural Product Library solubility dmso evaluation include AT13387, STA9090, and MPC3100. In particular, STA-9090 (ganetespib) is being evaluated over 25 clinical trials, including breast, lung, colorectal, and
hematologic tumors (http://www.clinicaltrials.gov/ct2/results?term=ganetespib&pg=1). In this report, we have used a panel of pancreatic and colorectal carcinoma cell lines and primary cultures derived from human tumors to test the effects of 17-AAG and NVP-AUY922. In addition, we were interested in finding molecular determinants
of sensitivity or resistance to these drugs. We have determined that pancreatic carcinoma Ivacaftor molecular weight PANC-1 and CFPAC-1 cells were resistant to 17-AAG both in anchorage-dependent and -independent growth assays (Figure 1 and Figure 2). The colorectal carcinoma cell line Caco-2 was also resistant to 17-AAG (Figure 1). Pancreatic and colorectal sensitive cell lines underwent cell death upon 17-AAG treatment, as indicated by an increase in the sub-G1 phase of the cell cycle, whereas resistant cell lines did not (Figure 3). However, all cell lines were sensitive to NVP-AUY922. A previous report has shown that NVP-AUY922 is able to inhibit migratory and invasive properties of pancreatic cancer cells . However, when we performed anchorage-dependent Protirelin and -independent growth assays in primary cultures obtained from colorectal tumors, we found that the HCUVA-CC-34 was not very responsive to 17-AAG and even less responsive to NVP-AUY922. We have demonstrated in this report that EGFR, HER2, HER3, and HER4 are Hsp90 client proteins that are depleted upon 17-AAG treatment in sensitive pancreatic and colorectal cell lines such as IMIM-PC-1, IMIM-PC-2, SW620, or HT-29 but not in resistant PANC-1, CFPAC-1, or Caco-2 cells within 4 or 8 hours (Figure 4 and Figure 5
and data not shown). Not only HER receptors but also the signaling pathways downstream this class of tyrosine kinase receptors were also downregulated in sensitive cell lines, since Akt protein levels, Akt, RSK1, p70S6k, RPS6, and ERK2 phosphorylation levels diminished upon 17-AAG treatment (Figure 4, Figure 5 and Figure 6). Albeit HER2 and HER3 protein levels were partially downregulated by 17-AAG in some of the resistant cells, the signaling pathways in these cells were unaltered. NVP-AUY922 was also able to deplete HER receptors in all cell lines tested within 4 or 8 hours (Figure 4 and Figure 5 and data not shown). The induction of Hsp70 was observed in sensitive cell lines to 17-AAG very rapidly, within 4 or 8 hours of treatment.